How to Treat Patients after Serious Adverse Effects Caused by TNF Inhibitors?
Biological agents are widely used in the treatment of autoimmune rheumatic disorders. We report on serious adverse events during treatment with anti-tumor necrosis factor antibody in two of our patients with juvenile idiopathic arthritis. One patient was treated with a biological agent due to juveni...
Main Authors: | Saša Sršen, Eugenija Marušić, Vitomir Metličić, Luka Stričević, Marijan Frković, Marija Jelušić |
---|---|
Format: | Article |
Language: | English |
Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2020-01-01
|
Series: | Acta Clinica Croatica |
Subjects: | |
Online Access: | https://hrcak.srce.hr/file/352039 |
Similar Items
Similar Items
-
Comparison of Different Diagnostic Guidelines for the Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: Single Centre Experience
by: Matea Kronja, et al.
Published: (2018-01-01) -
Where Is Pediatric Rheumatology Going, and Why a New Section of Frontiers in Pediatrics?
by: Rolando Cimaz
Published: (2020-06-01) -
Serious Neurological Adverse Events of Ceftriaxone
by: Clémence Lacroix, et al.
Published: (2021-05-01) -
A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
by: Athimalaipet V. Ramanan, et al.
Published: (2018-02-01) -
Rheumatologic Manifestations in Iranian Patients with Autoimmune Thyroid Diseases
by: Sharabeh Hezarkhani, et al.
Published: (2014-10-01)